PL EN


Preferences help
enabled [disable] Abstract
Number of results
2014 | 61 | 1 | 29-32
Article title

The study of cellular cytotoxicity of argireline® - an anti-aging peptide

Content
Title variants
Languages of publication
EN
Abstracts
EN
Argireline® is well know, innovative anti-aging product used in the cosmetic market. This short chain peptide is used as active ingredient in dermal ointment and creams. Argireline® prevents formation of skin lines and wrinkles in a very similar way to the botulinum toxin (Botox), inhibiting neurotransmitter release at the neuromuscular junction. Argireline® does not require under skin muscle injections and it is believed to be relatively safe. However, despite the fact that some toxicity data has been provided by the product manufacturer, there is an evident lack of reliable information about cytotoxicity of argireline® in the literature. The aim of the presented study was to estimate the antiproliferation effect of argireline® solution in several concentrations. The influence of argireline® on cellular proliferation was examined against: human embryonic kidney HEK-293 cell line, human neuroblastoma IMR-32 cell line, and human primary skin fibroblasts. Tests were performed using formazan-based cell proliferation assay: EZ4U, which allows to measure the efficiency of mitochondrial oxidative activity in living cells. The argireline® inhibitory concentration, IC50 values were calculated and the results were compared to the IC50 value of the reference compound: doxorubicin. In conclusion, the considered method resulted in dose-dependent argireline® anti-proliferation effects. However, the significant cytotoxicity of argireline® solution was observed under 18 to 10 000 fold higher concentrations (depending on cells that were examined) in comparison to doxorubicin.
Publisher

Year
Volume
61
Issue
1
Pages
29-32
Physical description
Dates
published
2014
received
2013-10-15
revised
2014-01-09
accepted
2014-01-22
(unknown)
2014-03-17
Contributors
  • Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Kraków, Poland
  • Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Kraków, Poland
  • Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Kraków, Poland
author
  • Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Kraków, Poland
  • Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Kraków, Poland
References
  • Blanes-Mira C, Clemente J (2002) A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci 24: 303-310.
  • Cheng NC, Van Roy N, Chan A, Beitsma M, Westerveld A, Speleman F, Versteeg R (1995) Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification. Oncogene 10: 291-297.
  • Chen YA, Scheller RH (2001) SNARE-mediated membrane fusion. Nat Rev Mol Cell Biol 2: 98-106.
  • Gorouhi F, Maibach HI (2009) Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci 31: 327-345.
  • Kerns EH, Di L, (2008) Drug-like properties: Concepts, structure design and methods. Academic Press, Burlington, MA.
  • Krzysztoń-Russjan J, Książek I, Anuszewska E (2009) Porównanie użyteczności testów MTT i EZ4U stosowanych do oceny cytotoksyczności ksenobiotykow. Farm Pol 65: 395-402 (in Polish).
  • Lipotec S.A. Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides. European patent: WO 00/64932, 2002.
  • Lupo MP, Cole AL (2007) Cosmeceutical peptides. Dermatol Ther 20: 343-349.
  • Malich G, Markovic B, Winder C (1997) The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 124: 179-192.
  • Smith R (2001) Animal research: the need for a middle ground: Let's promote the three Rs of animal research: replacement, reduction, and refinement. BMJ: Brit Med J 322: 248.
  • Tumilowicz JJ, Nichols WW, Cholon JJ, Greene AE (1970) Definition of a continuous human cell line derived from neuroblastoma. Cancer Res 30: 2110-2118.
  • Zhang L, Falla TJ (2009) Cosmeceuticals and peptides. Clin Dermatol 27: 485-494.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv61p29kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.